替比夫定治疗HBeAg阳性慢性乙型肝炎的近期疗效观察

目的研究替比夫定治疗HBeAg阳性慢性乙型肝炎的近期疗效。方法78例HBeAg阳性慢性乙型肝炎患者随机分为两组，治疗组45例采用替比夫定治疗，对照组33例采用拉米夫定治疗，疗程48周，定期观察两组疗效。结果治疗48周后，两组患者在ALT复常率和HBeAg转换率比较，无统计学差异（P〉0．05）。治疗过程中定期比较两组患者HBVDNA阴转率和HBeAg阴转率，差异均有统计学意义（P〈0．05）。治疗48周时替比夫定组血清HBVDNA自基线下降值为6．07log10，与对照组相比有统计学差异（P〈0．01）。结论替比夫定治疗可以快速、有效降低HBVDNA，促进HBeAg阴转，其安全性和耐受性良好。

The efficacy of telbivudine in treatment of HBeAg-positive chronic hepatitis B patients

Aim To evaluate the clinical efficacy of telbivudine in treatment of HBeAg-positive chronic hepatitis B patients. Methods There 78 HBeAg-positive chronic hepatitis B patients were randomly assigned to a daily 600 mg telbivudine treatment group or daily 100 mg lamivudine group for 48 weeks. The clinical efficacy of the 2 groups were analyzed. Results At week 48,there were no significant differences in the normal rate of ALT and the conversion rate of HBeAg between the 2 groups （P〉0.05）,while the negative conversion rate of serum HBV-DNA and HBeAg were deffemet significantly（P〈0.05）. The mean reductions of serum HBV DNA were significantly greater in the telbivudine-treated patients than the lamivudine-treated group （6.2 log10 vs 5.15 log10,P〈0.01）. Conclusion Telbivudine can rapidly and effectively inhibit the replication of HBV DNA and promote the negative conversion of HBeA in the patients with chronic hepatitis B. In addition, telbivudine is safe and well-tolerated.